Syneos Health, Inc. Class A Common Stock

SYNH

Market cap $4.46B

Colin Shannon Appointed Executive Chairman Seasoned Executive Further Strengthens Company's Leadership Team MORRISVILLE, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Costa Panagos as CEO and a member of the Company's Board of Directors, effective immediately.

Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE ®  Crossject expanding market access activities in preparation for filing for marketing authorization ZEPIZURE®, previously known as ZENEO® Midazolam, is separately contracted with BARDA for U.S. advanced regulatory development and specific supply to the Strategic National Stockpile Dijon, France, January 4, 2024, 18:00 CET -- Crossject (ISIN: FR0011716265; uronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, has engaged Syneos Health, a leading fully integrated biopharmaceutical solutions organization, to prepare for the commercial launch of Crossject's ZEPIZURE® innovative rescue therapy for epileptic seizures in the U.S. Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for ZEPIZURE®. Syneos Health brings a strong U.S. presence and significant expertise in commercializing new therapies for Crossject.